12.2
投与レジメン：部分薬物動態パラメータ
薬物動態学においては、薬物の完全な薬物動態プロファイルが明らかにならないことも少なくありません。そのため、動物試験や臨床試験から包括的な薬物動態データが得られない場合、薬物動態学者は適切な投与レジメンを決定するために一定の合理的な仮定を設ける必要があります。よく用いられる仮定の一つに、生物学的利用能…
多くの薬物の完全な薬物動態プロファイルは、多くの場合、不明または利用できません。
したがって、研究者は、薬物の安全性、有効性、治療範囲に応じて、薬物動態データなしで投与計画を計算するために、いくつかの仮定を立てる必要があります。
一般的な仮定の 1 つは、バイオアベイラビリティ係数 F を 1 または 100% に設定することです。
これにより、薬剤が完全に吸収されない場合、患者は過剰投薬ではなく、投薬不足になります。
集団薬物動態は、患者からの限られた血清薬物濃度サンプルで平均的な患者集団特性を使用します。
治療薬モニタリングにおける集団薬物動態の使用は、コンピューター化されたデータベースの利用可能性と観察データ分析のための統計ツールの開発により増加しています。
View the full transcript and gain access to JoVE Core videos
Q1: Why do researchers set the bioavailability factor to 1 when complete pharmacokinetic data is unavailable?
Setting the bioavailability factor, F, to 1 or 100% ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated. This conservative assumption prioritizes patient safety by erring on the side of caution when complete pharmacokinetic profiles remain unknown or unavailable.
Q2: What factors guide the selection of assumptions for dosage regimen calculations?
Pharmacokineticists select assumptions based on three key factors: the drug's safety profile, its efficacy, and its therapeutic range. These criteria ensure that educated assumptions about bioavailability and other parameters lead to appropriate dosage regimens that balance therapeutic effectiveness with patient protection.
Q3: How does population pharmacokinetics help when individual drug data is incomplete?
Population pharmacokinetics uses average patient population characteristics combined with limited serum drug concentration samples from patients to estimate dosing parameters. This approach has increased in therapeutic drug monitoring due to computerized databases and advanced statistical tools for analyzing observational data.
Q4: What role do computerized databases play in modern dosage regimen development?
Computerized databases enable population pharmacokinetics by storing and organizing large amounts of patient data and serum drug concentration information. Combined with statistical tools for observational data analysis, these databases facilitate the calculation of appropriate dosage regimens without requiring complete individual pharmacokinetic profiles.
Q5: Why is population pharmacokinetics increasingly used in therapeutic drug monitoring?
Population pharmacokinetics has gained prominence in therapeutic drug monitoring because it provides a practical alternative when complete pharmacokinetic profiles are unavailable. The availability of computerized databases and development of statistical tools for observational data analysis make this approach feasible and reliable for clinical practice.
Q6: What happens if a drug's bioavailability assumption is set too high?
If the bioavailability factor is set too high, patients may receive insufficient drug doses, resulting in undermedication and reduced therapeutic effectiveness. This is why researchers conservatively set F to 1 or 100% when complete absorption data is unknown, prioritizing patient safety over potential overmedication risks.
Q7: How do statistical tools support dosage regimen calculations in population pharmacokinetics?
Statistical tools designed for observational data analysis enable pharmacokineticists to extract meaningful pharmacokinetic information from limited serum drug concentration samples across patient populations. These tools help calculate reliable dosage regimens by identifying patterns and relationships in population-level data when individual complete profiles are unavailable.